.Attributes Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ innovative bosom cancer and also active or steady mind metastases revealed regular intracranial activity and also wide spread efficiency of T-DXd.